SA
Sign upLog In
ADILW

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for addiction and related disorders. Its lead product candidate, AD04, targets alcohol use disorder and has shown promise in clinical trials, positioning the company within a niche market with significant unmet needs.

HealthcareBiotechnologylow - the company has no current revenue, and its operational costs are primarily fixed due to R&D expenditures.

Business Overview

01Product sales from AD04 (0% of total, as it is not yet commercialized)
02Partnerships and collaborations (0% of total, as no revenue reported)

Adial Pharmaceuticals aims to generate revenue through the commercialization of its lead product, AD04, which is designed to reduce alcohol consumption in patients with alcohol use disorder. The company has a competitive advantage due to its unique mechanism of action and the lack of effective treatments currently available in the market.

What Moves the Stock

Clinical trial results for AD04, particularly Phase 3 outcomes

Regulatory approvals from the FDA or other health authorities

Partnership announcements with larger pharmaceutical companies

Market sentiment regarding addiction treatment advancements

Watch on Earnings
Progress in clinical trialsPartnership revenue potentialCash burn rate

Risk Factors

Regulatory risks associated with drug approvals and compliance

Technological disruption in treatment methodologies for addiction

Emerging therapies from competitors targeting similar disorders

Potential for larger pharmaceutical companies to enter the market with more resources

High cash burn rate due to ongoing clinical trials without revenue

Dependence on future financing to support R&D efforts

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

low - the demand for addiction treatments is relatively inelastic, as they address critical health issues regardless of economic conditions.

Interest Rates

minimal - the company has no debt, so rising interest rates do not impact financing costs directly. However, higher rates could affect investor sentiment and valuations.

Credit

minimal - Adial Pharmaceuticals currently has no debt, reducing its exposure to credit conditions.

Live Conditions
Russell 2000 FuturesDow Jones FuturesS&P 500 Futures

Profile

growth - investors looking for high-risk, high-reward opportunities in the biotech sector.

high - the stock has exhibited extreme volatility, with a 3-month return of -91%.

Key Metrics to Watch
Clinical trial enrollment rates for AD04
FDA feedback on drug applications
Cash runway and funding status
Market trends in addiction treatment

Explore More

Stock Comparison

Compare equities side by side

52-Week Highs Breakout

Stocks breaking to new annual highs

52-Week Lows Oversold

S&P 500 oversold value screener

Trending Momentum

Relative strength momentum leaders

Earnings Calendar

Upcoming earnings dates & reports

S&P 500 Screener

Filter and sort all 500 stocks

Strategy Focus List

Continuous multi-factor scoring & catalyst forensics

Market Movers

Today's biggest gainers and losers

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.